Intellia Therapeutics, Inc. (NTLA) vs PDS Biotechnology Corporation (PDSB)
A side-by-side comparison of Intellia Therapeutics, Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
NTLA
Intellia Therapeutics, Inc.
$12.26HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
PDSB
PDS Biotechnology Corporation
$0.75HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — NTLA vs PDSB
growth of $100 · dividends reinvested · last 10yNTLA -28.8% (-3.3%/yr)PDSB -99.7% (-43.4%/yr)NTLA compounded faster over this window
Log scale — wide-divergence pair
NTLA PDSB
NTLA vs PDSB: by the numbers
- •NTLA is the larger company ($1.71B vs $42M market cap).
- •Both run net losses; PDSB's is the smaller (0.00% vs -672.16% net margin).
Metrics side by side
Valuation
| Metric | NTLA | PDSB |
|---|---|---|
| P/S ratio | 28.79 | N/A |
| P/B ratio | 2.35 | N/A |
Profitability
| Metric | NTLA | PDSB |
|---|---|---|
| Gross margin | 76.47% | 0.00% |
| Operating margin | -651.67% | 0.00% |
| Net margin | -672.16% | 0.00% |
| ROE | -54.96% | N/A |
| ROIC | -54.45% | -3699.99% |
Growth (annualized)
| Metric | NTLA | PDSB |
|---|---|---|
| Revenue CAGR (5Y) | 7.31% | N/A |
| Total return CAGR (5Y) | -38.17% | -45.19% |
Frequently asked
- How have NTLA and PDSB total returns compared?
- Over the past 10 years, NTLA delivered -3.34% and PDSB delivered -43.37% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.